Compile Data Set for Download or QSAR
maximum 50k data
Found 51 Enz. Inhib. hit(s) with all data for assayid = 2 entry = 6979
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM60589(6-{[6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4...)
Affinity DataIC50:  3.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM100714(US8507676, 63 | US9062045, Comparator No. 2)
Affinity DataIC50:  4.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163243(US9062045, Comparator No. 1 (JNJ-38877605))
Affinity DataIC50:  4.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163240(US9062045, 84)
Affinity DataIC50:  6.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163219(US9062045, 59)
Affinity DataIC50:  6.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50396934(CHEMBL2001019 | CHEMBL2170804 | US9062045, Compara...)
Affinity DataIC50:  7.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163246(US9062045, Reference Example No. 73)
Affinity DataIC50:  7.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163211(US9062045, 51)
Affinity DataIC50:  7.00E+3nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163217(US9062045, 57)
Affinity DataIC50:  1.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163225(US9062045, 68)
Affinity DataIC50:  1.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163238(US9062045, 82)
Affinity DataIC50:  1.10E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163221(US9062045, 61)
Affinity DataIC50:  1.20E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163233(US9062045, 77)
Affinity DataIC50:  1.20E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163207(US9062045, 47)
Affinity DataIC50:  1.20E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163218(US9062045, 58)
Affinity DataIC50:  1.30E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163214(US9062045, 54)
Affinity DataIC50:  1.30E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163213(US9062045, 53)
Affinity DataIC50:  1.40E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163232(US9062045, 76)
Affinity DataIC50:  1.40E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163164(US9062045, 3)
Affinity DataIC50:  1.40E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163244(US9062045, Reference Example No. 63)
Affinity DataIC50:  1.50E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163181(US9062045, 22)
Affinity DataIC50:  1.50E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163195(US9062045, 35A)
Affinity DataIC50:  1.60E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163186(US9062045, 27)
Affinity DataIC50:  1.70E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163171(US9062045, 10)
Affinity DataIC50:  1.70E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163216(US9062045, 56)
Affinity DataIC50:  1.70E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163230(US9062045, 74)
Affinity DataIC50:  1.80E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163222(US9062045, 62)
Affinity DataIC50:  1.80E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163204(US9062045, 43)
Affinity DataIC50:  2.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163239(US9062045, 83)
Affinity DataIC50:  2.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163174(US9062045, 13)
Affinity DataIC50:  2.40E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163189(US9062045, 30)
Affinity DataIC50:  2.50E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163191(US9062045, 32)
Affinity DataIC50:  2.60E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163242(US9062045, 86)
Affinity DataIC50:  2.70E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163234(US9062045, 78)
Affinity DataIC50:  2.80E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163203(US9062045, 42)
Affinity DataIC50:  2.90E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163245(US9062045, Reference Example No. 66)
Affinity DataIC50: >3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163182(US9062045, 23)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163169(US9062045, 8)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163167(US9062045, 6)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163215(US9062045, 55)
Affinity DataIC50: >3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163241(US9062045, 85)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163190(US9062045, 31)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163236(US9062045, 80)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163235(US9062045, 79)
Affinity DataIC50: >3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163193(US9062045, 34)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163227(US9062045, 70)
Affinity DataIC50: >3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163226(US9062045, 69)
Affinity DataIC50: >3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163176(US9062045, 15)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163210(US9062045, 50)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-inhibited 3',5'-cyclic phosphodiesterase 3A/3B(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM163180(US9062045, 21)
Affinity DataIC50:  3.00E+4nMAssay Description:The kinase assay is based on the LanthaScreen technology. LanthaScreen is the detection of Time-Resolved Fluorescence Resonance Energy Transfer (TR-F...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 51 total ) | Next | Last >>
Jump to: